JamesDavidBrandtMD

Ophthalmology • Sacramento, CA

Anterior Segment Related, Cataract Related, Glaucoma Related, Pediatric & Strabismus

Professor & Director, Glaucoma Service

Join to view full profile

Dr. Brandt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Brandt's full profile

Already have an account?

Office
4860 Y St
# Uc
Sacramento, CA 95817
Phone+1 916-734-6818

Fax+1 916-734-0411

Summary

James D. Brandt, MD, is Professor of Ophthalmology & Vision Science, Director of the Glaucoma Service and Vice-Chair for International Programs & New Technologies at the University of California, Davis in Sacramento, California.

After receiving a BS degree from Yale University and an MD degree from Harvard Medical School, he pursued a two-year post-doctoral research fellowship in glaucoma-related pharmacology and cell biology at the Schepens Eye Research Institute in Boston before his residency at the USC/LA County/Doheny Eye Institute. He completed a glaucoma fellowship at the Wills Eye Hospital before joining the UC Davis faculty in 1989.

Dr. Brandt’s clinical practice is limited to glaucoma, with a particular focus on infantile and pediatric glaucoma. Dr. Brandt is a frequent volunteer faculty member with ORBIS International, traveling worldwide to train glaucoma specialists in the management of pediatric glaucoma.

Dr. Brandt has served as the Principal Investigator of numerous clinical trials, including the Ocular Hypertension Treatment Study (OHTS). As an OHTS principal investigator, Dr. Brandt initiated the effort to measure central corneal thickness (CCT) as a potential risk factor for glaucoma and has continued to investigate the role of CCT in glaucoma diagnosis and pathogenesis.

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalFellowship, Glaucoma, 1988 - 1989
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Ophthalmology, 1985 - 1988
Eye Research InstitutePost-Doctoral Fellowship, 1983 - 1985
University of MinnesotaInternship, Surgery, 1982 - 1983
Harvard Medical SchoolClass of 1982, M.D.
Yale UniversityBS, Biology, 1973 - 1978

Certifications & Licensure

CA State Medical License 1984 - 2026
MA State Medical License 1983 - 2011
PA State Medical License 1988 - 2000
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
Senior Achievement Award American Academy of Ophthalmology, 2004
Secretariat Award American Academy of Ophthalmology, 2004
Best Doctors in America 1996, 1998
Honor Award American Academy of Ophthalmology, 1996
Heed Ophthalmology Fellowship 1989
Super Doctor SuperDoctors.com
Fellow (FAAO) American Academy of Ophthalmology
Join now to see all

Clinical Trials

Primary Tube Versus Trabeculectomy Study Start of enrollment: 2008 Apr 01
Completed
Phase 4
Baerveldt Plate Area Comparison (BPAC) Start of enrollment: 2010 Jun 01
Terminated
Not Applicable
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension Start of enrollment: 2013 Oct 23
Completed
Phase 2

Publications & Presentations

PubMed

Visual Field Progression in the Ocular Hypertension Treatment Study.
Mae O Gordon, Dale K Heuer, Eve J Higginbotham, Richard K Parrish, Lei Liu
American Journal of Ophthalmology. 2024-12-06
Glaucoma Following Cataract Surgery in Children-Finally, a Clue.
James D Brandt, Suma P Shankar
JAMA Ophthalmology. 2023-09-01
Reply.
Steven J Gedde, Kin Sheng Lim, Keith Barton, Saurabh Goyal, Iqbal I Ahmed
Ophthalmology. 2023-07-01

Journal Articles

Visual field quality control in the Ocular Hypertension Treatment Study (OHTS).
Keltner JL, Johnson CA,Cello KE, Bandermann SE, Fan J, Levine RA, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group, Journal of Glaucoma 16(8):665-669
The Ocular Hypertension Treatment Study: Topical Ocular Hypotensive Medication Delays or Prevents Primary Open Angle Glaucoma in African American Individuals.
Higginbotham EJ, Gordon MO, Beiser JA, Drake MV, Bennett GR, Wilson MR, Kass MA for the Ocular Hypertension Treatment Study Group, Archives of Ophthalmology 122:813-820
Baseline risk factors for the development of POAG in the Ocular Hypertension Treatment Study.
Coleman AL, Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study Group, American Journal of Ophthalmology 138(4):684-685
Incorporating the results of the Ocular Hypertension Treatment Study into clinical practice. Letter to Editor.
Kass MA, Gordon MO, Kymes SM for the Ocular Hypertension Treatment Study Group, Archives of Ophthalmology 123:1021-1022
Normal visual field test results following glaucomatous visual field endpoints in the Ocular Hypertension Treatment Study.
Keltner JL, Johnson CA, Levine RA, Fan JJ, Cello KE, Kass MA, Gordon MO for the Ocular Hypertension Treatment Study Group, Archives of Ophthalmology 123:1201-1206
Test-retest reproducibility of optic disk deterioration detected from stereophotographs by masked graders.
Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz M-C, Vandenbrouke R, Kass MA, Gordon MO for the Ocular Hypertension Study Group, American Journal of Ophthalmology 140:762-764
Asymmetries and visual field summaries as predictors of glaucoma in the Ocular Hypertension Treatment Study (OHTS).
Levine RA, Demirel S, Fan JJ, Keltner JL, Johnson CA, Kass MA for the Ocular Hypertension Study Group, Investigative Ophthalmology & Visual Science 47:3896-3903
The association between glaucomatous visual fields and optic nerve head features in the Ocular Hypertension Treatment Study.
Keltner JL, Johnson CA, Anderson DR Levine RA, Fan JJ, Cello KE, Quigley HA, Budenz DL, Parrish RK, II, Kass MA, Gordon MO for the Ocular Hypertension Treatment Stud..., Ophthalmology 113(9):1603-1612
Topical Ocular Hypotensive Medication and Lens Opacification: Evidence From the Ocular Hypertension Treatment Study.
Herman DC, Gordon MO, Beiser JA, Chylack LT, Lamping KA, Schein OD, Soltau JB, Kass MA and the Ocular Hypertension Treatment Study Group, American Journal of Ophthalmology 142:800– 800
Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study.
Budenz DL, Anderson DR, Feuer WJ, Beiser JA, Schiffman J, Parrish RK, II, Piltz-Seymour JR, Gordon MO, Kass MA for the Ocular Hypertension Treatment Study Group, Ophthalmology 113(12):2137-2143
A validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension.
The Ocular Hypertension Treatment Study Group and the European Glaucoma Prevention Study (EGPS) Group, Ophthalmology 114(1):10-19
Comparison of initial intraocular pressure response to topical ß-adrenergic antagonists and prostaglandin analogues in African-Americans and white individuals in the ...
Mansberger SL, Hughes BA, Gordon MO, Spaner SD, Beiser JA, Cioffi GA, Kass MA and the Ocular Hypertension Treatment Study Group, Archives of Ophthalmology 125(4):454-459
Classification of visual field abnormalities in the Ocular Hypertension Treatment Study.
Johnson CA, Keltner JL, Cello KE, Edwards M, Bandermann SE, Kass MA, Gordon MO for the Ocular Hypertension Treatment Study Group, Archives of Ophthalmology 121:643-650
Diabetes and Glaucoma.
Kass MA, Gordon MO for the Ocular Hypertension Treatment Study Group, Archives of Ophthalmology 126(5):746-a-7
Is a History of Diabetes Mellitus Protective Against developing Primary Open-Angle Glaucoma?
Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study Group, Archives of Ophthalmology 126:280-1
Variability of Intraocular Pressure Measruements in Observation Participants in the Ocular Hypertension Treatment Study.
Bhorade AM, Wilson BS, Gordon MO, Weinreb RN, Kass MA and the Ocular Hypertension Treatment Study Group, Ophthalmology 116:717-724
Delaying Treatment of Ocular Hypertension – The Ocular Hypertension Treatment Study.
Kass MA, Gordon MO, Gao F, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish RK, Wilson MR for the Ocular Hypertension Treatment Study Group, Archives of Ophthalmology 128(3):276-287
The Incidence of Retinal Vein Occlusion in the Ocular Hypertension Treatment Study.
Barnett EM, Fantin, A, Wilson BS, Kass MA, Gordon MO for the Ocular Hypertension Treatment Study Group, Ophthalmology 117:484-488
The Utility of the Monocular Trial: Data from the Ocular Hypertension Treatment Study.
Bhorade AM, Wilson BS, Gordon MO, Palmberg P, Weinreb RN, Miller E, Chang RT, Kass MA for the Ocular Hypertension Treatment Study Group, Ophthalmology 117:2047-2054
Six-month Comparison of Bimatoprost Once-Daily and Twice-Daily with Timolol Twice-Daily in Patients with Elevated Intraocular Pressure.
Sherwood, Mark J. & James D. Brandt for the Hypotensive Lipid Study Groups 1 and 2, Survey of Ophthalmology 45(Suppl 4):S361-S368
One-Year, Randomized Study Comparing Bimatoprost and Timolol in Glaucoma and Ocular Hypertension.
Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, Vandenburgh AM, Chen K, Whitcup SM for the Bimatoprost Study Groups 1 and 2, Archives of Ophthalmology 120(10):1286-1293
The Ahmed Baerveldt Comparison Study – Methodology, Baseline Patient Characteristics, and Intraoperative Complications.
Barton K, Gedde SJ, Budenz DL, Feuer WJ, Schiffman J for the Ahmed Baerveldt Comparison Study Group, Ophthalmology 118(3):435-442
Treatment Outcomes in the he Ahmed Baerveldt Comparison Study after 1 Year of Follow-up.
Budenz DL, Barton K, Feuer WJ, Schiffman J, Costa VP, Godfrey DG, Buys YM for the Ahmed Baerveldt Comparison Study Group, Ophthalmology 118(3):443-452
A 12-Month, Multicenter, Randomized, Double-Masked, Parallel-Group Comparison of Timolol-LA Once Daily and Timolol Maleate Ophthalmic Solution Twice Daily in the Tre...
Mundorf TK; Ogawa T; Naka H; Novak GD and Crockett RS for the US Istalol Study Group, Clinical Therapeutics 26(4):541-551
Droplet-based interfacial capacitive sensing.
Nie B, Xing S, Brandt JD & Pan T, Lab on a chip
Join now to see all

Books/Book Chapters

Cornea.
Chapter: Glaucoma after Penetrating Keratoplasty
Brandt JD, Lim MC & O’Day DGEditors: Mannis & Kratchmer.Elsevier, LondonEdition 2,
Medical Treatment of Glaucoma.
Chapter: Medical Management of Glaucoma in Infants and Children
Page 267 - 271Brandt JDEditors: Weinreb RN, Araie M, Susanna R, Goldberg I, Migdal C & Liebmann J.Kugler Publications, Amsterdam
Pearls of Glaucoma Consultation.
Chapter: Incorporating Central Corneal Thickness into Clinical Practice
Brandt JDEditors: Caprioli, Coleman, Law & Giaconi.Springer, Germany
Ophthalmology.
Chapter: Congenital Glaucoma
Brandt JDEditors: Yanoff & Duker.Mosby International, LondonEdition 3,
Duane’s Clinical Ophthalmology.
Chapter: Surgery for Congenital Glaucoma
Brandt JD & Suhr, AWJ. B. Lippincott, Philadelphia
Curbside Consultation in Glaucoma – 49 Clinical Questions.
Chapter: Should I measure central corneal thickness in all glaucoma patients? All Glaucoma Suspects
Brandt JDEditors: Heuer, Gedde & Lewis.Slack, Thorofare
Glaucoma.
Chapter: The Impact of Central Corneal Thickness and Corneal Biomechanics on Tonometry
Brandt JD, Roberts CR, Sherwood MB & Sheets CWEditors: Shaarawy, Sherwood, Hitchings & Crowston.Elsevier, London
Answers in Glaucoma.
Chapter: What is the practical importance of pachymetry in the clinical evaluation of glaucoma
Brandt JDEditors: Susanna & Weinreb.Cultura Médica, Rio de Janeiro
Ophthalmology.
Chapter: What have we learned from the major glaucoma clinical trials
Brandt JD & Wilson MREditors: Grehn & Stamper.Springer, Germany
Optics for Ophthalmologists – A Board-Review Manual
Sadun, AA & Brandt JDSpringer-Verlag, New York
Ophthalmology.
Chapter: Congenital Glaucoma
Page 1475 - 1481Brandt JDEditors: Yanoff & Duker.Mosby International, LondonEdition 2,
Ophthalmology.
Chapter: Trabeculotomy and Goniotomy
Page 1569 - 1576Brandt JDEditors: Yanoff & Duker.Mosby International, LondonEdition 2,
Duane’s Clinical Ophthalmology.
Chapter: Surgery for Congenital Glaucoma
Brandt JDJ. B. Lippincott, Philadelphia
Ophthalmology.
Chapter: Congenital Glaucoma
Brandt JDEditors: Yanoff & Duker.Mosby International, London
Ophthalmology.
Chapter: Trabeculotomy and Goniotomy
Brandt JDEditors: Yanoff & Duker.Mosby International, London
Duane’s Clinical Ophthalmology.
Chapter: Surgery for Congenital Glaucoma
Brandt JDJ. B. Lippincott, PhiladelphiaEdition 6,
Consensus Series 4.
Chapter: Intraocular Pressure
Weinreb RN, Brandt JDEditors: Garway-Heath D & Medeiros F.Kugler Publications, The Netherlands
Join now to see all

Lectures

35th Annual UC Davis Health System Eye Center Ophthalmology Symposium - Big Topics on the Big Island: An Update of Comprehensive Ophthalmology 2012
UC Davis Health System, Waikoloa, Hawaii - 6/13/2012
35th Annual Ophthalmology Symposium: Big Topics on the Big Island; An Update of Comprehensive Ophthalmology
UC Davis Health System, Waikoloa, Hawaii - 6/13/2012
American Glaucoma Society 22nd Annual Meeting
American Glaucoma Society (AGS), New York, New York - 3/1/2012
Tonometry.
Singapore
Should Every Patient in a Glaucoma Practice undergo Pachymetry.
Subspecialty Day Anaheim, CA
The Tube versus Trabeculectomy Study.
Massachusetts Eye & Ear Infirmary Harvard Medical School Boston, MA
Re-Inventing Tonometry for the 21 st Century.
Massachusetts Eye & Ear Infirmary Harvard Medical School Boston, MA, 2006
Why combination medicines?
Athens, Greece
Assessing Glaucoma Risk – New tools for the Clinician [Keynote].
Athens, Greece
Understanding Corneal Thickness in the Management of Glaucoma.
World Congress of Ophthalmology São Paulo, Brazil, 2005
IOP should not be adjusted for corneal thickness – Point/Counterpoint
American Academy of Ophthalmology Subspecialty Day Chicago, Illinois
Individualizing Treatment based on the Major Glaucoma Trials.
Asia-Oceanic Glaucoma Symposium / Autralia-New Zealand Glaucoma Club Cairns, Queensland, Australia
Central Corneal Thickness in Glaucoma Diagnosis & Management.
5 th International Glaucoma Symposium Cape Town, South Africa
Glaucoma Drainage Implants – A re-appraisal of their role.
Royal Australia & New Zealand College of Ophthalmologists Tasmania Branch Meeting Hobart, Australi
Glaucoma in Infants & Children.
Royal Australia & New Zealand College of Ophthalmologists Tasmania Branch Meeting Hobart, Australia
The Ocular Hypertension Treatment Study.
Royal Australia & New Zealand College of Ophthalmologists Queensland Branch Journal Club Brisbane, A
The Role of Corneal Thickness in Glaucoma Management.
4 th International Glaucoma Symposium Barcelona, Spain
Decision-making after trabeculectomy has failed.
Singapore
Global Risk Assessment in the Glaucoma Patient.
Durham, NC
Ophthalmology’s Botanical Heritage.
Durham, NC
What did we learn from OHTS?
Glaucoma Symposium Budapest, Hungary
The OHTS-EGPS Risk Model.
Glaucoma Symposium Budapest, Hungary
The role of CCT in interpreting IOP level.
University of Illinois Glaucoma Symposium Grand Cayman, BWI, 2007
Tonometry and CCT.
19 th Annual Meeting of the Japanese Glaucoma Society Osaka, Japan
The OHTS-EGPS Risk Model.
University of Illinois Glaucoma Symposium Grand Cayman, BWI
Join now to see all

Other

LEO Clinical Update on Glaucoma.
Mark B. Sherwood, James D. Brandt, Neil T
San Francisco
LEO Clinical Update on Glaucoma.
Mark B. Sherwood, James D. Brandt, Neil T
San Francisco
Measuring Outflow Resistance of an Eye.
Pan, Tingrui & Brandt, James D
A method for enhancing outflow of aqueous humor in treatment of glaucoma.
Brandt, James D., Martha E. O’Donnell & Fitz-Roy E. Curry
A method for enhancing outflow of aqueous humor in treatment of glaucoma.
Brandt, James D., Martha E. O’Donnell & Fitz-Roy E. Curry
A method for enhancing outflow of aqueous humor in treatment of glaucoma.
Brandt, James D., Martha E. O’Donnell & Fitz-Roy E. Curry
A method for enhancing outflow of aqueous humor in treatment of glaucoma.
Brandt, James D., Martha E. O’Donnell & Fitz-Roy E. Curry
Join now to see all

Press Mentions

$UC Davis Health Eye Center 1st to Try Microshunt for Refractory Childhood Glaucoma$
UC Davis Health Eye Center 1st to Try Microshunt for Refractory Childhood GlaucomaNovember 17th, 2022
Silicone Ring May Be Superior to Drops for Glaucoma PatientsMay 5th, 2016